| 1 |
Lara MS, Brunson A, Wun T, et al. Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California cancer registry analysis[J]. Lung Cancer, 2014, 85(2): 264-269.
|
| 2 |
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075.
|
| 3 |
Butte MJ, Penã-Cruz V, Kim MJ, et al. Interaction of human PD-L1 and B7-1[J]. Mol Immunol, 2008, 45(13): 3567-3572.
|
| 4 |
Barnet MB, Cooper WA, Boyer MJ, et al. Immunotherapy in Non-Small Cell Lung Cancer: Shifting prognostic paradigms[J]. J Clin Med, 2018, 7(6): pii: E151.
|
| 5 |
Robert C, Ribas A, Wolchok JD, et al. Antiprogrammed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial [J]. Lancet, 2014, 384: 1109-1117.
|
| 6 |
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non small-cell lung cancer[J]. N Engl J Med, 2016, 375(19): 1823-1833.
|
| 7 |
de Mello RA, Veloso AF, Esrom Catarina P, et al. Potential role of immunotherapy in advanced non-small-cell lung cancer[J]. Onco Targets Ther, 2016, 10: 21-30.
|
| 8 |
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123-135.
|
| 9 |
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced non squamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
|
| 10 |
Brahmer JR, Govindan R, Anders RA, et al. The Society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)[J]. J Immunother Cancer, 2018, 6(1): 75.
|
| 11 |
Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2016, 34(25): 2969-2979.
|
| 12 |
Carbone DP, Reck M, Paz-Ares L, et al. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer[J]. N Engl J Med, 2017, 376(25): 2415-2426.
|
| 13 |
Borghaei H, Hellmann MD, Paz-Ares LG, et al. Nivolumab (Nivo) ＋platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from Check Mate 227[J]. J Clin Oncol, 2018, 36(15_suppl): 9001.
|
| 14 |
Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in lung Cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22): 2093-2104.
|
| 15 |
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. New Engl J Med, 2015, 372(21): 2018-2028.
|
| 16 |
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomized controlled trial[J]. Lancet, 2016, 387(10027): 1540-1550.
|
| 17 |
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non small-cell lung cancer [J]. N Engl J Med, 2016, 375(19): 1823-1833.
|
| 18 |
Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11): 1497-1508.
|
| 19 |
Paz-Ares LG, Luft A, Tafreshi A, et al. Phase 3 study of carboplatin paclitaxel/nab-paclitaxel (Chemo) with or without pembrolizumab (Pembro) for patients (Pts) with metastatic squamous (Sq) non-small cell lung cancer(NSCLC)[J]. J Clin Oncol, 2018, 36(15 suppl): 105.
|
| 20 |
Fehrenbacher L, Spira A, Ballinger M, et al. POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial[J]. Lancet, 2016, 387: 1837-1846.
|
| 21 |
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial[J]. Lancet, 2017, 389(10066): 255-265.
|
| 22 |
Brahmer JR, Govindan R, Anders RA, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)[J]. J Immunother Cancer, 2018, 6(1): 75.
|
| 23 |
Jotte RM, Cappuzzo F, Vynnychenko I, et al. IMpower131: Primary PFS and safety analysis of a randomized phase Ⅲ study of atezolizumab＋carboplatin＋paclitaxel or nab-paclitaxel vs carboplatin＋nab-paclitaxel as1L therapy in advanced squamous NSCLC[J]. J Clin Oncol, 2018, 36(18suppl): LBA9000.
|
| 24 |
Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after Chemoradiotherapy in stage Ⅲ non-small-cell lung Cancer[J]. N Engl J Med, 2017, 377(20): 1919-1929.
|
| 25 |
Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and anti tumour activity in a phase 1b study of combined check point blockade with anti-PD-L1 (durvalumab) andanti-CTLA4 (tremelimumab) in non-small cell lung cancer [J]．Lancet Oncol, 2016, 17(3): 299-308.
|
| 26 |
Gulley JL, Rajan A, Spigel DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial [J]. Lancet Oncol, 2017, 18(5): 599-610.
|
| 27 |
Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase IIstudy[J]. J Clin Oncol, 2012, 30(17): 2046-2054.
|
| 28 |
Govindan R, Szczesna A, Ahn M, et al. Phase Ⅲ trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer[J]. J Clin Oncol, 2017, 35(30): 3449-3457.
|
| 29 |
Reck M, Bondarenko I, Luft A, et al. Ipilimumab incombination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, muhicenter phase 2 trial[J]. Ann Oncol, 2013, 24(1): 75-83.
|
| 30 |
Ahmadzada T, Kao S, Reid G, et al. An update on predictive biomarkers for treatment selection in Non-Small Cell Lung Cancer[J]. J Clin Med, 2018, 7(6): 153.
|
| 31 |
Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the study of lung cancer, and the Association for Molecular Pathology[J]. J Mol Diagn, 2018, 20(2): 129-159.
|
| 32 |
Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome[J]. Nat Rev Cancer, 2012, 12(4): 298-306.
|
| 33 |
Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance[J]. Nature, 2014, 515(7528): 568-571.
|
| 34 |
Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints[J]. Cancer Discov, 2015, 5(1): 43-51.
|
| 35 |
Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota[J]. Science, 2015, 350(6264): 1079-1084.
|
| 36 |
Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients[J]. Science, 2018, 359(6371): 97-103.
|